|Bid||0.0000 x 900|
|Ask||0.0000 x 1800|
|Day's Range||2.4700 - 2.6000|
|52 Week Range||2.2500 - 17.1200|
|Beta (3Y Monthly)||3.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
EXTON, Pa., May 02, 2019 -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the.
Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. On the other...
Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today announced that Cristina Csimma, Pharm. D., M.H.P. and Michael Dougherty have been appointed to the Board of Directors, effective April 10, 2019.
Idera Pharmaceuticals, Inc. (“Idera”) (IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology and rare disease indications, today is reporting clinical and translational data from the ILLUMINATE-101 Phase 1 study which explored the role of investigational tilsotolimod as monotherapy in patients with various refractory solid tumors. In the poster presentation entitled, “Activation of Innate and Adaptive Immunity Using Intratumoral Tilsotolimod (IMO-2125) as Monotherapy in Patients with Refractory Solid Tumors: a Phase 1b Study (ILLUMINATE-101)” (abstract number 4062), Hani Babiker, M.D., Assistant Professor of Medicine and Associate Director of the Phase 1 Program at the University of Arizona Cancer Center, presented results from this study.
Pennsylvania's life sciences industry honored its own Wednesday night as awards where handed out at Life Sciences Pennsylvania's annual dinner. The event at the Pennsylvania Convention Center drew a record crowd of more than 1,300 people. The awards include two named in honor of biotech pioneer's Hubert J. P. Schoemaker, the co-founder of Centocor, and Frank Baldino Jr., the co-founder of Cephalon.
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really hate to see fellow investors lose their hard-earned money. Spare aRead More...
– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 –– ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 –– ILLUMINATE-206 Trial Expected to Initiate Q2 2019.
Idera Pharmaceuticals, Inc. (IDRA) today announced completion of enrollment into the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*) in patients with unresectable or metastatic melanoma following failure of PD-1 inhibitor treatment. 52 patients have been dosed in the trial which included two separate patient groups. The company completed the targeted enrollment of 40 patients in the primary enrollment population, constituting patients who are naïve to prior ipilimumab treatment in the metastatic setting. This patient population mirrors the enrollment for the ILLUMINATE-301 phase 3 pivotal trial. The secondary exploratory enrollment population targeted up to 20 patients who had prior ipilimumab treatment in the metastatic setting.
Travis CI, the popular Berlin-based open-source continuous integration service, has been acquired by Idera, a company that offers a number of SQL database management and administration tools for both on-premises and cloud applications. The move comes at a time when other continuous integration services, including the likes of Circle CI, seem to be taking market share away from Travis CI. Idera, which itself is owned by private equity firm TA Associates, says that Travis is complementary to its current testing tools business and that the acquisition will benefit its current customers.
Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...
Idera Pharmaceuticals, Inc. (IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. An archived version will also be available on the company’s website after the event for 90 days. As a convenience to investors, a copy of the company’s presentation will be posted on the Idera corporate website at 7:30 a.m. Eastern Time on Monday, January 7, 2019.
Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director at J.P. Morgan. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University. “Carol brings a unique set of skills and experience that traverses the financial and corporate biotech landscape and will be incredibly valuable to our board as we continue to advance Idera’s mission to bring forward options for patients suffering from life-threatening diseases and ultimately create long-term shareholder value,” stated James Geraghty, Chairman of Idera’s Board of Directors.
NEW YORK, NY / ACCESSWIRE / December 17, 2018 / Both Johnson & Johnson and Idera Pharmaceuticals were big losers in Friday’s trading session. J&J tumbled on a Reuters story that alleged it knew about its baby powder having asbestos for decades while Idera announced data from an ongoing phase 2 trial that were actually encouraging. Johnson & Johnson shares were tanking on Friday, on a Retuers story that the company had known for decades that its baby powder has asbestos.
Idera Pharmaceuticals, Inc. (IDRA) today is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy®*).
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of intratumoral tilsotolimod and ipilimumab for unresectable or metastatic melanoma following failure of anti-PD-1 inhibitor treatment prior to the opening of the U.S. financial markets on Friday, December 14, 2018. To participate in the conference call, please dial (844) 882-7837 (domestic) and (574) 990-9824 (international). The webcast can be accessed live or in archived form in the “Investors” section of the company’s website at www.iderapharma.com. The company will be posting a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call.
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
If you want to know who really controls Idera Pharmaceuticals Inc (NASDAQ:IDRA), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Exton, Pennsylvania-based company said it had a loss of 43 cents. Losses, adjusted for gains related to mergers and acquisitions, were 46 cents per share. The results surpassed ...
– Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 –– Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 -- Idera.